

Current and future cancer staging after neoadjuvant tre

Ca-A Cancer Journal for Clinicians

71, 140-148

DOI: [10.3322/caac.21640](https://doi.org/10.3322/caac.21640)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Perioperative Safety and Effectiveness of Neoadjuvant Therapy with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Plus Apatinib in Locally Advanced Gastric Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 2279-2286.	0.9	5
2	The safety and efficacy of neoadjuvant programmed death 1 inhibitor therapy with surgical resection in stage IIIA non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 486-486.	0.7	17
3	Autophagy Blockade by Ai Du Qing Formula Promotes Chemosensitivity of Breast Cancer Stem Cells Via GRP78/ β 2-Catenin/ABCG2 Axis. <i>Frontiers in Pharmacology</i> , 2021, 12, 659297.	1.6	13
4	Apatinib with doxorubicin and ifosfamide as neoadjuvant therapy for high-risk soft tissue sarcomas: a retrospective cohort study. <i>Investigational New Drugs</i> , 2021, 39, 1724-1731.	1.2	2
5	Comparison of outcomes between neoadjuvant imatinib and upfront surgery in patients with localized rectal GIST: An inverse probability of treatment weighting analysis. <i>Journal of Surgical Oncology</i> , 2021, 124, 1442-1450.	0.8	6
6	Significant decrease of the pathological stage I rectal carcinoma in the era of neoadjuvant therapy—A matter of concern. <i>European Journal of Cancer</i> , 2021, 159, 275-282.	1.3	0
8	Effects of N6-Methyladenosine Modification on Cancer Progression: Molecular Mechanisms and Cancer Therapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
9	Biomimetic nanotherapeutics: Employing nanoghosts to fight melanoma. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 177, 157-174.	2.0	12
10	Black phosphorous nanomaterials as a new paradigm for postoperative tumor treatment regimens. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	5
11	Nodal downstaging to ypN0 after neoadjuvant chemotherapy positively impacts on survival of cT4N+ GC/GEJ patients. <i>Journal of Surgical Oncology</i> , 2022, 126, 1403-1412.	0.8	4
12	Cell Division Cycle-Associated Protein 3 (CDCA3) Is a Potential Biomarker for Clinical Prognosis and Immunotherapy in Pan-Cancer. <i>BioMed Research International</i> , 2022, 2022, 1-28.	0.9	4
13	Electrostatic Induced Peptide Hydrogels for pH-Controllable Doxorubicin Release and Antitumor Activity. <i>ChemistrySelect</i> , 2022, 7, .	0.7	3
14	Evolution of Wifl: Expansion of Wifl Notation After Intervention. <i>International Journal of Lower Extremity Wounds</i> , 0, , 153473462211228.	0.6	1
15	Direct and indirect effects of IFN- γ 2b in malignancy treatment: not only an archer but also an arrow. <i>Biomarker Research</i> , 2022, 10, .	2.8	10
16	Esophageal Cancer Staging. <i>Thoracic Surgery Clinics</i> , 2022, 32, 437-445.	0.4	4
17	Non-Invasive and Real-Time Monitoring of the Breast Cancer Metastasis Degree via Metabolomics. <i>Cancers</i> , 2022, 14, 5589.	1.7	1
18	Cancer nanomedicine in preoperative therapeutics: Nanotechnology-enabled neoadjuvant chemotherapy, radiotherapy, immunotherapy, and phototherapy. <i>Bioactive Materials</i> , 2023, 24, 136-152.	8.6	14
19	Automatic treatment outcome prediction with Deeplnteg based on multimodal radiological images in rectal cancer. <i>Heliyon</i> , 2023, 9, e13094.	1.4	0

#	ARTICLE	IF	CITATIONS
20	Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within breast cancer subtypes and stages among older women: a SEER-Medicare analysis. <i>Breast Cancer</i> , 2023, 30, 489-496.	1.3	1
21	Therapy resistance and metastasis. <i>Clinical and Experimental Metastasis</i> , 2023, 40, 123-124.	1.7	0
23	Systematic pan-cancer analysis identifies transmembrane protein 158 as a potential therapeutic, prognostic and immunological biomarker. <i>Functional and Integrative Genomics</i> , 2023, 23, .	1.4	4
24	Cholecystectomy and risk of liver disease: a systematic review and meta-analysis of 27 million individuals. <i>International Journal of Surgery</i> , 2023, 109, 1420-1429.	1.1	4
25	The application of radiomics in esophageal cancer: Predicting the response after neoadjuvant therapy. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
26	Pan-Cancer Analysis Reveals PPRC1 as a Novel Prognostic Biomarker in Ovarian Cancer and Hepatocellular Carcinoma. <i>Medicina (Lithuania)</i> , 2023, 59, 784.	0.8	1
27	“Major pathologic response” in lymph nodes: a modified nodal classification for non-small cell lung cancer patients treated with neoadjuvant immunochemotherapy. <i>Experimental Hematology and Oncology</i> , 2023, 12, .	2.0	2